medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-0-90-96medsovet-1667Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYЛЕФЛУНОМИД ПРИ РАННЕМ РЕВМАТОИДНОМ АРТРИТЕ: ВКЛЮЧЕНИЕ В СТРАТЕГИЮ ЛЕЧЕНИЯ И ПЕРСПЕКТИВЫLEFLUNOMIDE IN EARLY RHEUMATOID ARTHRITIS: INCLUSION IN THE TREATMENT STRATEGY AND PROSPECTSКаратеевД. Е.KarateevD. E.

д.м.н.

MD

 

ОрловаЕ. В.OrlovaE. V.Научно-исследовательский институт ревматологии им. В.А. Насоновой, МоскваРоссияNasonova Scientific and Research Institute, MoscowRussian Federation20173012201701S9096Copyright © Каратеев Д.Е., Орлова Е.В., 20172017Каратеев Д.Е., Орлова Е.В.Karateev D.E., Orlova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1667

По данным литературы, лефлуномид сопоставим по эффективности и безопасности с метотрексатом, в том числе у пациентов с ранним ревматоидным артритом (РА). Препарат продолжает играть важную роль в лечении больных ранним РА и может рассматриваться в качестве основного синтетического базисного противовоспалительного препарата, который должен назначаться при невозможности терапии эффективными дозами метотрексата. Комбинация метотрексата и лефлуномида, уменьшая потребность в биологической терапии, может быть одним из эффективных способов преодоления толерантности к метотрексату. Роль данной комбинации в стратегии лечения раннего РА может быть недооценена, целесообразно продолжение исследований в этом направлении.

 

 

 

 

According to the literature, Leflunomide is comparable in efficacy and safety with methotrexate, including patients with early rheumatoid arthritis (RA). The drug continues to play an important role in the treatment of patients with early RA and may be considered as a main synthetic base anti-inflammatory drug which should be administered in case of impossibility of treatment by effective doses of methotrexate. The combination of Methotrexate and Leflunomide, reducing the need for biological therapy, may be an effective way to overcome tolerance to Methotrexate. The role of this combination treatment strategies for early RA may be underestimated, it is expedient to conduct further research in this direction.

ранний ревматоидный артритлефлуномидметотрексатстратегия леченияearly rheumatoid arthritisLeflunomideMethotrexatetreatment strategyReferencesНасонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008, 290–331.Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008, 290–331.Ревматология: клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010, 752 с.Ревматология: клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010, 752 с.Каратеев Д.Е. Ретроспективная оценка многолетней базисной терапии у больных ревматоидным артритом. Науч-практич ревматол, 2003, 3: 32–6.Каратеев Д.Е. Ретроспективная оценка многолетней базисной терапии у больных ревматоидным артритом. Науч-практич ревматол, 2003, 3: 32–6.Emery P, Breedveld FC, Dougados M et al. http://www.ncbi.nlm.nih.gov/ pubmed?term=Kalden%20JR%5BAuthor%5D&c author=true&cauthor_uid=11874828Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis, 2002, 61: 290–7.Emery P, Breedveld FC, Dougados M et al. http://www.ncbi.nlm.nih.gov/ pubmed?term=Kalden%20JR%5BAuthor%5D&c author=true&cauthor_uid=11874828Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis, 2002, 61: 290–7.Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis, 1995, 54: 944–7.Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis, 1995, 54: 944–7.Emery P. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol, 1995, 34(2): 87–90.Emery P. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol, 1995, 34(2): 87–90.Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2007, 66(1): 34–45.Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2007, 66(1): 34–45.Насонов Е.Л. Фармакотерапия ревматоидного артрита с позиций доказательной медицины: новые рекомендации. РМЖ, 2002, 10(6): 294–302.Насонов Е.Л. Фармакотерапия ревматоидного артрита с позиций доказательной медицины: новые рекомендации. РМЖ, 2002, 10(6): 294–302.Насонов Е.Л. Почему необходима ранняя диагностика и лечение ревматоидного артрита? РМЖ, 2002, 10(22): 1009–14.Насонов Е.Л. Почему необходима ранняя диагностика и лечение ревматоидного артрита? РМЖ, 2002, 10(22): 1009–14.Nell VP, Machold KP, Eberl G et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2004, 43(7): 906–14.Nell VP, Machold KP, Eberl G et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2004, 43(7): 906–14.Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med, 2001, 111: 446–51.Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med, 2001, 111: 446–51.Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a ran-domized trial. Ann Intern Med, 2007, 146: 406–15.Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a ran-domized trial. Ann Intern Med, 2007, 146: 406–15.Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet, 2004, 364: 263–9.Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet, 2004, 364: 263–9.Smolen JS, Aletaha D, Koeller M et al. New therapies for treatment of rheumatoid arthritis. Lancet, 2007, 370: 1861–74.Smolen JS, Aletaha D, Koeller M et al. New therapies for treatment of rheumatoid arthritis. Lancet, 2007, 370: 1861–74.Sokka T, Hetland ML, Mäkinen H et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. Arthritis Rheum, 2008, 58: 2642–51.Sokka T, Hetland ML, Mäkinen H et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. Arthritis Rheum, 2008, 58: 2642–51.Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis, 2010, 69: 631–7.Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis, 2010, 69: 631–7.Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis, 2010, 69(6): 964–75.Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis, 2010, 69(6): 964–75.Каратеев Д.Е., Лучихина Е.Л. Современная стратегия терапии ревматоидного артрита. РМЖ, 2012, 30: 1504–9.Каратеев Д.Е., Лучихина Е.Л. Современная стратегия терапии ревматоидного артрита. РМЖ, 2012, 30: 1504–9.Орлова Е.В., Каратеев Д.Е., Булгакова Н.А. Лечение ревматоидного артрита до достижения цели (Treat to Target): российская версия международных рекомендаций для пациентов. Науч-практич ревматол, 2013, 51(3): 246–54.Орлова Е.В., Каратеев Д.Е., Булгакова Н.А. Лечение ревматоидного артрита до достижения цели (Treat to Target): российская версия международных рекомендаций для пациентов. Науч-практич ревматол, 2013, 51(3): 246–54.Олюнин Ю.А. Целенаправленное лечение ревматоидного артрита: рекомендации международной комиссии (Treatment to target expert committee – Экспертная комиссия по целенаправленному лечению). Соврем ревматол, 2010, 3: 7-9.Олюнин Ю.А. Целенаправленное лечение ревматоидного артрита: рекомендации международной комиссии (Treatment to target expert committee – Экспертная комиссия по целенаправленному лечению). Соврем ревматол, 2010, 3: 7-9.Насонов Е.Л., Мазуров В.И., Каратеев Д.Е. и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология, 2014, 52(5): 477–494.Насонов Е.Л., Мазуров В.И., Каратеев Д.Е. и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология, 2014, 52(5): 477–494.Aletaha D, Neogri T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum, 2010, 62(9): 2569–81.Aletaha D, Neogri T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum, 2010, 62(9): 2569–81.Каратеев Д.Е., Олюнин Ю.А., Лучихина Е.Л. Новые классификационные критерии ревматоидного артрита EULAR/ACR 2010 – шаг вперед к ранней диагностике. Науч-практич ревматол, 2011, 1: 10–5.Каратеев Д.Е., Олюнин Ю.А., Лучихина Е.Л. Новые классификационные критерии ревматоидного артрита EULAR/ACR 2010 – шаг вперед к ранней диагностике. Науч-практич ревматол, 2011, 1: 10–5.Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis, 2014, 73: 492–509.Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis, 2014, 73: 492–509.Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Науч-практич ревматол 2013, 6(51):609–22.Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Науч-практич ревматол 2013, 6(51):609–22.Чичасова Н.В., Иголкина Е.В., Насонов Е.Л., Имаметдинова Г.Р. Лефлуномид в лечении ревматоидного артрита. РМЖ, 2013, 32: 1628–35.Чичасова Н.В., Иголкина Е.В., Насонов Е.Л., Имаметдинова Г.Р. Лефлуномид в лечении ревматоидного артрита. РМЖ, 2013, 32: 1628–35.Насонов Е.Л., Амирджанова В.Н., Беневоленская Л.И. и соавт. Лечение ревматоидного артрита. Клинические рекомендации. М.: Алмаз, 2006: 118 с.Насонов Е.Л., Амирджанова В.Н., Беневоленская Л.И. и соавт. Лечение ревматоидного артрита. Клинические рекомендации. М.: Алмаз, 2006: 118 с.Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet, 1999, 353(9149): 259–66.Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet, 1999, 353(9149): 259–66.Sharp JT, Strand V, Leung H et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum, 2000, 43(3): 495–505.Sharp JT, Strand V, Leung H et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum, 2000, 43(3): 495–505.Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med, 1999, 159(21): 2542–50.Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med, 1999, 159(21): 2542–50.Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis, 1999, 58(4): 220–5.Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis, 1999, 58(4): 220–5.Singh JA, Furst DE, Bharat A et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research, 2012, 64(5): 625–39.Singh JA, Furst DE, Bharat A et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research, 2012, 64(5): 625–39.Van der Heijde DM, van Riel PL, Gribnau FW et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damageVan der Heijde DM, van Riel PL, Gribnau FW et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damagein rheumatoid arthritis. Lancet, 1989, 333: 1036–8.in rheumatoid arthritis. Lancet, 1989, 333: 1036–8.Каратеев Д.Е. Лефлуномид в современной терапии ревматоидного артрита. РМЖ, 2010, 27: 1654–6.Каратеев Д.Е. Лефлуномид в современной терапии ревматоидного артрита. РМЖ, 2010, 27: 1654–6.Cohen S, Cannon GW, Schiff M et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum, 2001, 44(9): 1984–92.Cohen S, Cannon GW, Schiff M et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum, 2001, 44(9): 1984–92.Cohen S, Weaver A, Shiff M, Strand V. Two-year treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arthritis Rheum, 1999, 42(Suppl.): 271.Cohen S, Weaver A, Shiff M, Strand V. Two-year treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arthritis Rheum, 1999, 42(Suppl.): 271.Emery P, Breeveld FC, Lemmel EM et al. A com-paration ot the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford), 2000, 39: 655–65.Emery P, Breeveld FC, Lemmel EM et al. A com-paration ot the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford), 2000, 39: 655–65.Strand V, Tugwell P, Bombardier C et al. Function and health-related quality of life: results from a randomised controlled trial of ltflunomide vs methotrexate or placebo in patients with active rheumatoid arthritis. Arthr Rheum, 1999, 42(9): 1870–78.Strand V, Tugwell P, Bombardier C et al. Function and health-related quality of life: results from a randomised controlled trial of ltflunomide vs methotrexate or placebo in patients with active rheumatoid arthritis. Arthr Rheum, 1999, 42(9): 1870–78.Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double–blind, randomized, multi-centre trial. European Leflunomide Study Group. Lancet, 1999, 353: 259–66.Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double–blind, randomized, multi-centre trial. European Leflunomide Study Group. Lancet, 1999, 353: 259–66.Kalden JR, Scott DL, Smolen JS et al. Improved functional ability in patients with rheumatoid arthritis – long–term treatment with leflunomide versus sulfasalasine. J Rheumatol, 2001, 28(9): 1983–91.Kalden JR, Scott DL, Smolen JS et al. Improved functional ability in patients with rheumatoid arthritis – long–term treatment with leflunomide versus sulfasalasine. J Rheumatol, 2001, 28(9): 1983–91.Scott DL, Smolen JS, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double-blind, placebo-controled trial versus sulfasalazine. Ann Rheum Dis, 2001, 60: 913–23.Scott DL, Smolen JS, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double-blind, placebo-controled trial versus sulfasalazine. Ann Rheum Dis, 2001, 60: 913–23.Osiri M, Shea B, Robinson V et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev, 2003, (1): CD002047.Osiri M, Shea B, Robinson V et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev, 2003, (1): CD002047.Donahue KE, Gartlehner G, Jonas DE et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med, 2008, 148(2): 124–34.Donahue KE, Gartlehner G, Jonas DE et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med, 2008, 148(2): 124–34.Чичасова Н.В., Чижова К.А., Иголкина Е.В. и соавт. Новый базисный препарат для лечения ревматоидного артрита – (Арава (лефлуномид): опыт многомесячного применения. РМЖ, 2004, 2: 124–8.Чичасова Н.В., Чижова К.А., Иголкина Е.В. и соавт. Новый базисный препарат для лечения ревматоидного артрита – (Арава (лефлуномид): опыт многомесячного применения. РМЖ, 2004, 2: 124–8.Чичасова Н.В., Бродецкая К.А., Иголкина Е.В. и соавт. Опыт длительного применения лефлуномида (препарат Арава) у больных активным ревматоидным артритом. РМЖ, 2005, 13(8): 518–24.Чичасова Н.В., Бродецкая К.А., Иголкина Е.В. и соавт. Опыт длительного применения лефлуномида (препарат Арава) у больных активным ревматоидным артритом. РМЖ, 2005, 13(8): 518–24.Чичасова Н.В., Иголкина Е.В., Имаметдинова Г.Р., Насонов Е.Л. Лефлуномид в лечении раннего ревматоидного артрита. РМЖ, 2011, 10: 606–9.Чичасова Н.В., Иголкина Е.В., Имаметдинова Г.Р., Насонов Е.Л. Лефлуномид в лечении раннего ревматоидного артрита. РМЖ, 2011, 10: 606–9.Чичасова Н.В., Насонов Е.Л. Лефлуномид в лечении ревматических заболеваний. М.: МегаПро, 2010, 92 c.Чичасова Н.В., Насонов Е.Л. Лефлуномид в лечении ревматических заболеваний. М.: МегаПро, 2010, 92 c.Van der Heijde D, Kalden JR, Scott D et al. Longterm evaluation of radiologic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis, 2004, 63: 737–9.Van der Heijde D, Kalden JR, Scott D et al. Longterm evaluation of radiologic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis, 2004, 63: 737–9.Sharp J, Strand V, Leung H et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum, 2000, 43: 495–505.Sharp J, Strand V, Leung H et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum, 2000, 43: 495–505.Kalden JR, Schattenkirchen M, Sorensen H et al. Efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up. Arthr Rheum, 2003, 48: 1513–20.Kalden JR, Schattenkirchen M, Sorensen H et al. Efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up. Arthr Rheum, 2003, 48: 1513–20.Балабанова P.M., Каратеев Д.Е., Кашеваров Р.Ю. и др. Лефлуномид (Арава) при раннем ревматоидном артрите. Научно-практическая ревматология, 2005, 5: 31–4.Балабанова P.M., Каратеев Д.Е., Кашеваров Р.Ю. и др. Лефлуномид (Арава) при раннем ревматоидном артрите. Научно-практическая ревматология, 2005, 5: 31–4.Балабанова Р.М., Кашеваров Р.Ю., Олюнин Ю.А. Антидеструктивное действие лефлуномида при раннем ревматоидном артрите. Тер арх, 2006, 78(6): 6–10.Балабанова Р.М., Кашеваров Р.Ю., Олюнин Ю.А. Антидеструктивное действие лефлуномида при раннем ревматоидном артрите. Тер арх, 2006, 78(6): 6–10.Kashevarov R, Balabanova RM, Oliunin YA et al. Level of matrix metalloproteinase 3 and joint destruction rate in early RA treated with leflunomide and methotrexate. Ann Rheum Dis, 2006, 65(Suppl II): 341.Kashevarov R, Balabanova RM, Oliunin YA et al. Level of matrix metalloproteinase 3 and joint destruction rate in early RA treated with leflunomide and methotrexate. Ann Rheum Dis, 2006, 65(Suppl II): 341.Каратеев Д.Е. Лефлуномид в современной патогенетической терапии раннего ревматоидного артрита. РМЖ, 2007, 26: 2042–46.Каратеев Д.Е. Лефлуномид в современной патогенетической терапии раннего ревматоидного артрита. РМЖ, 2007, 26: 2042–46.Karateev DE, Luchikhina EL, Nasonov EL. High frequency of clinical remission in patient with early RA treated with leflunomide. Ann Rheum Dis, 2006, 65(Suppl 2): 341.Karateev DE, Luchikhina EL, Nasonov EL. High frequency of clinical remission in patient with early RA treated with leflunomide. Ann Rheum Dis, 2006, 65(Suppl 2): 341.Федоренко Е.В., Лукина Г.В., Сигидин Я.А. и соавт. Сравнительная эффективность современных методов терапии раннего ревматоидного артрита (предварительные результаты). Науч-практич ревматол, 2008, 4: 36–40.Федоренко Е.В., Лукина Г.В., Сигидин Я.А. и соавт. Сравнительная эффективность современных методов терапии раннего ревматоидного артрита (предварительные результаты). Науч-практич ревматол, 2008, 4: 36–40.Cutolo M, Bolosiu H, Perdriset G, LEADER Study Group. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology (Oxford), 2013, 52(6): 1132–40.Cutolo M, Bolosiu H, Perdriset G, LEADER Study Group. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. Rheumatology (Oxford), 2013, 52(6): 1132–40.Ren LM, Li R, Chen LN et al. Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. Int J Rheum Dis, 2016, 19(7): 651–7.Ren LM, Li R, Chen LN et al. Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. Int J Rheum Dis, 2016, 19(7): 651–7.Чичасова Н.В., Насонов Е.Л. Комбинированная терапия лефлуномидом и генно-инженерными биологическими препаратами. Соврем ревматол, 2011, 2: 43–9.Чичасова Н.В., Насонов Е.Л. Комбинированная терапия лефлуномидом и генно-инженерными биологическими препаратами. Соврем ревматол, 2011, 2: 43–9.Орлова Е.В. Место лефлуномида в современной стратегии лечения ревматоидного артрита. Трудный пациент, 2015, 13(3): 20–7.Орлова Е.В. Место лефлуномида в современной стратегии лечения ревматоидного артрита. Трудный пациент, 2015, 13(3): 20–7.Keen HI, Conaghan PG, Tett SE. Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf, 2013, 12(4): 581–8.Keen HI, Conaghan PG, Tett SE. Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf, 2013, 12(4): 581–8.Golicki D, Newada M, Lis J, Pol K, Hermanowski T, Tłustochowicz M. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn, 2012, 122(1-2): 22-32.Golicki D, Newada M, Lis J, Pol K, Hermanowski T, Tłustochowicz M. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn, 2012, 122(1-2): 22-32.Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis–results of a prospective non-interventional study. Clin Rheumatol, 2010 Aug, 29(8): 913-20. doi: 10.1007/s10067-010-1425-3.Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis–results of a prospective non-interventional study. Clin Rheumatol, 2010 Aug, 29(8): 913-20. doi: 10.1007/s10067-010-1425-3.Graudal N, Jü rgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum, 2010 Oct, 62(10): 2852-63. doi: 10.1002/art.27592.,Graudal N, Jü rgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum, 2010 Oct, 62(10): 2852-63. doi: 10.1002/art.27592.,Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev, 2010 Apr 14, 4: CD008495. doi: 10.1002/14651858.CD008495.Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev, 2010 Apr 14, 4: CD008495. doi: 10.1002/14651858.CD008495.Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L. Efficacy of conventional synthetic disease-modifying anti-rheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis, 2014 Mar, 73(3): 510-5. doi: 10.1136/annrheumdis-2013-204588.Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L. Efficacy of conventional synthetic disease-modifying anti-rheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis, 2014 Mar, 73(3): 510-5. doi: 10.1136/annrheumdis-2013-204588.Аlcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf, 2009, 32(12): 1123-34. doi: 10.2165/11316650-000000000-00000.Аlcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf, 2009, 32(12): 1123-34. doi: 10.2165/11316650-000000000-00000.Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ, 2016 Apr 21, 353: i1777. doi: 10.1136/ bmj.i1777.Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ, 2016 Apr 21, 353: i1777. doi: 10.1136/ bmj.i1777.Kremer JM. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum, 1999 Aug, 29(1): 14-26.Kremer JM. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum, 1999 Aug, 29(1): 14-26.Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum, 1999, 42(7): 1322–1328.Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum, 1999, 42(7): 1322–1328.Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2002, 137(9): 726–733.Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2002, 137(9): 726–733.Kremer J, Genovese M, Cannon GW et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol, 2004, 31(8): 1521–1531.Kremer J, Genovese M, Cannon GW et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol, 2004, 31(8): 1521–1531.Lee SS, Park YW, Park JJ et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol, 2009 Jan-Feb, 38(1): 11-4. doi: 10.1080/03009740802360632.Lee SS, Park YW, Park JJ et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol, 2009 Jan-Feb, 38(1): 11-4. doi: 10.1080/03009740802360632.Jones PB, White DH. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol, 2010 Nov 3, 2: 53-71.Jones PB, White DH. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol, 2010 Nov 3, 2: 53-71.Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum, 2000 Nov, 43(11): 2609-11.Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum, 2000 Nov, 43(11): 2609-11.Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU, Park YB. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther, 2012 Oct 29, 14(5): R232. doi: 10.1186/ar4075.Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU, Park YB. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther, 2012 Oct 29, 14(5): R232. doi: 10.1186/ar4075.Rodriguez-Rodriguez L, Jover-Jover JA, Fontsere O, Peña-Blanco RC, León L, Fernández-Gutierrez B, Abásolo L. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. Scand J Rheumatol, 2013, 42(6): 433-6. doi: 10.3109/03009742.2013.785590.Rodriguez-Rodriguez L, Jover-Jover JA, Fontsere O, Peña-Blanco RC, León L, Fernández-Gutierrez B, Abásolo L. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. Scand J Rheumatol, 2013, 42(6): 433-6. doi: 10.3109/03009742.2013.785590.Bird P, Griffiths H, Tymms K et al. The SMILE study – safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol, 2013 Mar, 40(3): 228-35. doi: 10.3899/jrheum.120922.Bird P, Griffiths H, Tymms K et al. The SMILE study – safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol, 2013 Mar, 40(3): 228-35. doi: 10.3899/jrheum.120922.Kaul A, O’Reilly DT, Slack RK, Collins D, Walmsley J, Duke O, Kiely PD. Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study. Rheumatology (Oxford), 2008 Sep, 47(9): 1430-1. doi: 10.1093/rheumatology/ken240.Kaul A, O’Reilly DT, Slack RK, Collins D, Walmsley J, Duke O, Kiely PD. Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study. Rheumatology (Oxford), 2008 Sep, 47(9): 1430-1. doi: 10.1093/rheumatology/ken240.Alves JA, Fialho SC, Morato EF, Castro GR, Zimmermann AF, Ribeiro GG, Neves FS, Pereira IA. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate. Rev Bras Reumatol, 2011 Mar-Apr, 51(2): 141-4.Alves JA, Fialho SC, Morato EF, Castro GR, Zimmermann AF, Ribeiro GG, Neves FS, Pereira IA. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate. Rev Bras Reumatol, 2011 Mar-Apr, 51(2): 141-4.Hodkinson B, Magomero KR, Tikly M. Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach. Ther Adv Musculoskelet Dis, 2016 Oct, 8(5): 172-179.Hodkinson B, Magomero KR, Tikly M. Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach. Ther Adv Musculoskelet Dis, 2016 Oct, 8(5): 172-179.Sakellariou GT, Sayegh FE, Kapetanos GA, Berberidis C. Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. Clin Rheumatol, 2012 Jan, 31(1): 163-7. doi: 10.1007/s10067-011-1842-y.Sakellariou GT, Sayegh FE, Kapetanos GA, Berberidis C. Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. Clin Rheumatol, 2012 Jan, 31(1): 163-7. doi: 10.1007/s10067-011-1842-y.Verschueren P, De Cock D, Corluy L et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis, 2016 Jul 18. pii: annrheumdis-2016-209212. doi: 10.1136 /annrheumdis-2016-209212. [Epub ahead of print].Verschueren P, De Cock D, Corluy L et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis, 2016 Jul 18. pii: annrheumdis-2016-209212. doi: 10.1136 /annrheumdis-2016-209212. [Epub ahead of print].Dougados M, Emery P, Lemmel E-M, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol, 2003, 30(12): 2572–2579.Dougados M, Emery P, Lemmel E-M, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol, 2003, 30(12): 2572–2579.Dougados M, Emery P, Lemmel EM, Zerbini CAF, Brin S, van Riel P. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis, 2005, 64(1): 44–51.Dougados M, Emery P, Lemmel EM, Zerbini CAF, Brin S, van Riel P. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis, 2005, 64(1): 44–51.

The authors declare that there are no conflicts of interest present.